Nektar Therapeutics (NKTR) Asset Writedowns and Impairment (2012 - 2025)

Nektar Therapeutics' Asset Writedowns and Impairment history runs 5 years deep, the most recent figure standing at $4.4 million for Q4 2025.

• In Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $4.4 million; the TTM figure through Dec 2025 stood at $4.4 million (down 46.68% YoY), while the FY2025 annual figure was $4.4 million, down 46.68% from the prior year.
• Asset Writedowns and Impairment for Q4 2025 stood at $4.4 million, down from $8.3 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $57.3 million in Q2 2022, with the low at -$1000.0 in Q4 2023.
• The 4-year median for Asset Writedowns and Impairment is $7.2 million (2022), against an average of $11.9 million.
• Peak annual rise in Asset Writedowns and Impairment reached 747.75% in 2023, while the deepest fall reached 100.01% in 2023.
• Nektar Therapeutics' Asset Writedowns and Impairment stood at $7.2 million in 2022, then tumbled by 100.01% to -$1000.0 in 2023, then soared by 833000.0% to $8.3 million in 2024, then plunged by 46.68% to $4.4 million in 2025.
• Business Quant data shows NKTR's Asset Writedowns and Impairment at $4.4 million in Q4 2025, $8.3 million in Q2 2024, and -$1000.0 in Q4 2023.